Rna Diagnostics News - Clinical trials expand, new patents filed, business and clinical experts support RDA


Winter 2013

Moving RDA to the Clinic

Rna Diagnostics (RnaDx) made significant progress in 2012 as we work to bring our cancer therapy response technology, RDA™, towards market. 
  • Accrual of patients to the RDA clinical trial at Sunnybrook Hospital, Toronto is progressing well. The trial is expanding to the Jewish General Hospital and Hotel Dieu in Montreal, Quebec. Recruitment of additional sites in Ontario and Quebec continues. 
  • The research collaboration with the Instituti Ospitaliere di Cremona (Drs. D. Generali and A. Bottini) on pre-existing clinical samples is underway. Samples from two clinical trials are now being analyzed at the RnaDx laboratory in Sudbury.
  • In December 2012, RnaDx participated in the San Antonio Breast Cancer Symposium which was attended by 9,000 breast cancer specialists. RDA was enthusiastically received by key opinion leaders from around the world. The Management Team met with the RnaDx Clinical Advisory Board to review recommendations on how RDA may be used to guide treatment decisions.
  • A scientific poster describing the application of RDA to radiation treatment of breast cancer was presented at the San Antonio Breast Cancer Symposium.

New Patent Filings

RnaDx recentlly filed two new patents. One is for assessment of therapeutic radiation efficacy by RDA and the other, a technology to enhance RDA identification of chemotherapy treatment response.

Business Advisory Board 

RnaDx has added two new members to its Business Advisory Board. Denis Ho, former Managing Director of Life Sciences Venture Capital at the Business Development Bank of Canada, brings over 20 years of biotech start-up governance to RnaDx. Paul Lucas, former CEO of GlaxoSmithKline Canada and current chair of Life Sciences Ontario, brings in-depth pharmaceutical industry market intelligence to the company.  

RnaDx Team with Cremona Collaboration in San Antonio

Dr. Maureen Trudeau, Dr. Danieli Generali, John Connolly,
Dr. Alberto Bottini, Dr. Ken Pritzker, Gino Ariano


The Management Team met with the RnaDx Clinical Advisory Board to review recommendationson how RDA may be used to guide treatment decisions.

Dr. Amadeo Parissenti, RnaDx Chief Scientific Officer

In the News

Dr. Parissenti and the research team at RnaDx' Sudbury Laboratory were featured on CTV News. View clip.

Rising Star Award

RnaDx was selected as runner-up for the Rising Star Award at BioPartnering FutureEurope in Brussels, Belgium.

Distinguished Pathologist Award

The Ontario Association of Pathologists honoured RnaDx CEO Dr. Ken Pritzker with this prestigious award. They applauded his leadership in laboratory medicine, research and teaching. More

Management Team

Ken Pritzker, MD, FRCPC
  President & CEO
Amadeo Parissenti, PhD
  Chief Scientific Officer
John Connolly, MBA
  VP Corporate Development
John Jordan, MBA, CMA
  Chief Financial Officer
Gino Ariano, BComm
  Director of Marketing
Laura Pritzker, PhD
  Principal Scientist

Clinical Advisory Board 

Maureen E. Trudeau, MA, MD, FRCPC, Canada

Gunter von Minckwitz, MD, PhD, Frankfurt, Germany

Michael Untch, MD, PhD, Berlin, Germany

Harry D. Bear, MD, PhD, Richmond, VA, USA

Rna Diagnostics Inc. is a Canadian molecular diagnostics company developing diagnostic tools to improve chemotherapy management.

Our mailing address is:
Rna Diagnostics Inc.
MaRS Centre, Heritage Building, 101 College Street, Suite HL20-4, Toronto, ON, Canada
Toronto, ON M5G 1L7

Add us to your address book
For more information contact:
John Connolly
VP Corporate Development